FDA-Drug2026-07-29Class IICHEMICAL
Major Pharmaceuticals levothyroxine tablets recalled for subpotency
What this means
Major Pharmaceuticals is recalling one lot of Levothyroxine Sodium Tablets, USP 125 mcg due to subpotency—meaning the tablets contain less active ingredient than expected. This affects lot #N02266 with an expiration date of 11/2026. The affected tablets were distributed nationwide.
- Check if you have levothyroxine from lot #N02266 (expiration 11/2026) by looking at your prescription bottle.
- Contact your pharmacy or doctor if you have this lot; do not stop taking your medication without medical guidance.
- Return the affected tablets to your pharmacy for disposal and replacement.
The agency's original wording
Hazard
Subpotent Drug
Intended for
Adults
Illnesses reported
None reported
Sold states
Nationwide in the USA.
Affected count
N/A
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Products
Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6955-61
Official notice
https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-0705-2026More Major Pharmaceuticals recalls
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotent drug
- FDA-Drug2026-07-29Major Pharmaceuticals Levothyroxine Sodium 112 mcg tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine 25 mcg tablets recalled for subpotency
- FDA-Drug2026-07-29Major Pharmaceuticals levothyroxine sodium tablets recalled for subpotent drug
Want us to check the next one for you?
We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.